UnitedHealthcare IV Tocilizumab Coverage Update | OpenPayer

Loading...

UnitedHealthcare IV Tocilizumab Coverage Update | OpenPayer

Coverage Criteria for Intravenous Tocilizumab

Polyarticular Juvenile Idiopathic Arthritis - Initial Therapy

Covered when ALL of the following are met

ref

title

Systemic Juvenile Idiopathic Arthritis - Initial and Continuation

Covered when ALL of the following are met

ALL of the following

Diagnosis of systemic juvenile idiopathic arthritis (SJIA).
Administration: Prescriber attestation that the patient or caregiver cannot be trained or are physically unable to self-administer (with explanation); dosing per FDA label for SJIA; not used in combination with another systemic targeted immunomodulator for the same indication; prescribed by or in consultation with a rheumatologist.
Initial authorization <= 12 months; continuation requires prior IV use and documentation of positive response

Giant Cell Arteritis - Initial and Continuation

Covered when ALL of the following are met

ALL of the following

Diagnosis of giant cell arteritis (GCA).
Administration: Prescriber attestation that patient or caregiver cannot be trained or are physically unable to self-administer; dosing per FDA label for GCA; not used in combination with another systemic targeted immunomodulator for the same indication; prescribed by or in consultation with a rheumatologist; initial authorization <= 12 months; continuation requires prior IV use and documentation of positive clinical response.

Cytokine Release Syndrome - Initial and Continuation

Covered when ALL of the following are met

ALL of the following

Diagnosis of cytokine release syndrome (CRS).
Triggering therapy: Patient has received CAR T-cell therapy or CD3-directed therapy (examples listed).
Dosing and duration: Tocilizumab dosed per FDA label for CRS; initial authorization for no more than 4 doses; continuation requires documentation of positive clinical response and ongoing symptoms; authorization for no more than 4 doses.4 doses

Acute Graft-Versus-Host Disease - Initial and Continuation

Covered when ALL of the following are met

ALL of the following

Diagnosis of steroid-refractory acute graft-versus-host disease (GVHD).
Concomitant therapy: Patient is receiving tocilizumab in combination with systemic corticosteroids OR patient is intolerant to systemic corticosteroid therapy.
Dosing and duration: Initial authorization for no more than 4 doses; continuation requires documentation of positive clinical response and ongoing acute GVHD; authorization for no more than 4 doses.4 doses

Acute GVHD (initial and continuation therapy)

Tocilizumab is proven and medically necessary when ALL of the following are met:

Acute GVHD initial therapy: For initial therapy: Diagnosis of steroid refractory acute GVHD; and one of: patient is receiving tocilizumab in combination with systemic corticosteroids OR patient is intolerant to systemic corticosteroid therapy; initial authorization is for no more than 4 doses.4 doses

Acute GVHD continuation therapy: For continuation: Documentation of positive clinical response; patient continues to experience acute GVHD; and one of: patient is receiving tocilizumab in combination with systemic corticosteroids OR patient is intolerant to systemic corticosteroid therapy; authorization is for no more than 4 doses.4 doses

Immune checkpoint inhibitor-related toxicities

Tocilizumab is proven and medically necessary when ALL of the following are met:

Checkpoint inhibitor-related inflammatory arthritis: Patient has recently received checkpoint inhibitor therapy; diagnosis of severe immunotherapy-related inflammatory arthritis; no symptom improvement after 7 days of starting high-dose corticosteroids; history of failure, contraindication, or intolerance to infliximab; and one of: patient is receiving tocilizumab in combination with systemic corticosteroids OR patient is intolerant to systemic corticosteroid therapy; authorization is for no more than 4 doses.4 doses

Guideline- and evidence-aligned coverage

Covered when consistent with clinical trial evidence and specialty guideline recommendations

RA and related indications: Use of tocilizumab for rheumatoid arthritis and related inflammatory conditions when supported by clinical evidence (e.g., ACT-RAY trial) and guideline recommendations is considered appropriaterefer to clinical judgment and guideline specifics

ACT-RAY showed treat-to-target strategies with TCZ can achieve drug-free remission in a subset; NCCN and ACR provide indication-specific guidance

NCCN-supported indications

NCCN-recommended oncology and toxicity uses

NCCN indications: Tocilizumab is recommended (NCCN 2A) for cytokine release syndrome related to blinatumomab, supportive care for CRS, Castleman's disease, steroid-refractory acute GVHD as additional therapy, management of certain immune checkpoint inhibitor-related toxicities, and CAR T-cell-related toxicities with dosing considerationsfollow NCCN dosing frequency limits

Assess need for repeat dosing; do not exceed NCCN recommended maximums

ACR guideline considerations for coverage

ACR 2021 RA guideline-based sequencing and treatment goals

ACR-aligned sequencing: Follow treat-to-target strategy; prefer methotrexate as initial csDMARD in many patients and reserve biologic/targeted DMARDs (including tocilizumab) for patients not at target after adequate csDMARD therapy or when otherwise indicatedinitiate/titrate methotrexate to >=15 mg/week within 4-6 weeks when appropriate

Recommendations include conditional/strong preferences regarding methotrexate, csDMARDs, addition/switching to bDMARDs/tsDMARDs, and discontinuation strategies

Treatment modification recommendations (adult inflammatory arthritis)

Conditionally recommended sequencing and modification options from clinical guidelines:

Treatment modification cluster: Recommendations include: add a bDMARD or tsDMARD over triple therapy for patients on maximally tolerated methotrexate who are not at target; switch to a bDMARD/tsDMARD of a different class over same-class switch for patients not at target; add/switch to DMARDs over continuation or initiation/escalation of glucocorticoids; add/switch to DMARDs (with or without IA glucocorticoids) over IA glucocorticoids alone for patients on DMARDs not at target; when at target >=6 months prefer continuation at current dose over dose reduction, dose reduction over gradual discontinuation, and gradual discontinuation over abrupt discontinuation; gradual discontinuation preferences among sulfasalazine, hydroxychloroquine, methotrexate and bDMARD/tsDMARD as specified.

All recommendations described as conditional in source guideline.

Population-specific recommendations

Conditional and strong recommendations for specific comorbidities and patient groups:

Subcutaneous nodules: Methotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules and moderate-to-high disease activity; if progressive nodules, switching off methotrexate is conditionally recommended.

Pulmonary disease: Methotrexate is conditionally recommended over alternative DMARDs for inflammatory arthritis patients with mild/stable airway or parenchymal lung disease or incidental imaging findings with moderate-to-high disease activity.

Lymphoproliferative disorder: Rituximab is conditionally recommended over other DMARDs for patients with prior lymphoproliferative disorder for which rituximab is approved and moderate-to-high disease activity.

Heart failure: For NYHA class III or IV heart failure with inadequate response to csDMARDs, addition of a non-TNF inhibitor bDMARD or tsDMARD is conditionally recommended over adding a TNF inhibitor; switching to a non-TNF agent is conditionally recommended over continuation of a TNF inhibitor if heart failure develops while on a TNF inhibitor.

Juvenile idiopathic arthritis (JIA) recommendations

Guideline recommendations for children/adolescents with JIA and polyarthritis:

JIA biologic therapy: When initiating a biologic (etanercept, adalimumab, golimumab, abatacept, or tocilizumab), combination therapy with a DMARD is conditionally recommended over biologic monotherapy; for moderate/high disease activity (cJADAS-10 > 2.5) subsequent therapy: adding a biologic to DMARD monotherapy is conditionally recommended over changing DMARDs or triple therapy; if on first TNFi, switching to a non-TNFi biologic (tocilizumab or abatacept) is conditionally recommended over a second TNFi unless good initial response was seen; if on second biologic, TNFi, abatacept, or tocilizumab are conditionally recommended over rituximab.cJADAS-10 > 2.5

Giant cell arteritis (GCA) recommendations

Guideline recommendations for GCA management with tocilizumab:

GCA newly diagnosed: For newly diagnosed GCA, oral glucocorticoids with tocilizumab is conditionally recommended over oral glucocorticoids alone.

GCA with extracranial involvement: For GCA with active extracranial large vessel involvement, oral glucocorticoids combined with a nonglucocorticoid immunosuppressive agent (e.g., tocilizumab, methotrexate) is conditionally recommended over glucocorticoids alone.active extracranial large vessel involvement

GCA relapse with cranial symptoms: For GCA relapsing with cranial symptoms on glucocorticoids, adding tocilizumab and increasing glucocorticoids is conditionally recommended over adding methotrexate and increasing glucocorticoids.disease relapse with cranial symptoms

This policy applies only to tocilizumab products administered by intravenous infusion. Self‑administered subcutaneous tocilizumab formulations are handled through the pharmacy benefit and are not covered under this medical‑benefit policy.

The inclusion of a procedure or diagnosis code in this policy is for reference only and does not by itself indicate that the service is covered or not covered. Benefit coverage is determined by federal, state, or contractual plan requirements and applicable laws; other policies or guidelines may also apply.

No explicit exclusions are listed in the provided coverage excerpt. Clinical contexts from NCCN and ACR guidance are referenced to define appropriate indications and sequencing, but those guideline references in this section do not themselves constitute policy exclusions.

Information about FDA approvals and indications is included for context and clinical reference, but FDA approval alone is not a basis for coverage. Coverage determinations must follow applicable benefit plan requirements and related contractual or regulatory obligations.

This excerpt does not present a standalone list titled “Not Medically Necessary.” However, ACR guideline recommendations cited in the policy emphasize sequencing—such as initial use of methotrexate or appropriate csDMARD strategies—so initiation of a biologic without adequate prior csDMARD therapy may not align with guideline‑based expectations used to inform medical‑necessity determinations.

There are no explicit statements in this section declaring specific uses as Not Medically Necessary. FDA labeling is presented for informational purposes only, and actual coverage decisions should be made in accordance with the member’s benefit plan and applicable federal/state requirements.

Coding and Diagnosis Codes

Covered HCPCS/CodesmixedCovered

J3262	Injection, tocilizumab, 1 mg
Q5133	Injection, tocilizumab-bavi (Tofidence), biosimilar, 1 mg
Q5135	Injection, tocilizumab-aazg (Tyenne), biosimilar, 1 mg
Q5156	Injection, tocilizumab-anoh (Avtozma), biosimilar, 1 mg

Diagnosis Codes — GVHD / CRSICD-10Covered

D89.810	Acute graft-versus-host disease
D89.831	Cytokine release syndrome, grade 1
D89.832	Cytokine release syndrome, grade 2
D89.833	Cytokine release syndrome, grade 3
D89.834	Cytokine release syndrome, grade 4
D89.835	Cytokine release syndrome, grade 5
D89.839	Cytokine release syndrome, grade unspecified

Diagnosis Codes — Juvenile rheumatoid arthritis (selected)ICD-10Covered

M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand

1–10 of 17

1/2

Diagnosis Codes — Rheumatoid and related (partial list)ICD-10

M05.00	Felty's syndrome, unspecified site
M05.011	Felty's syndrome, right shoulder
M05.012	Felty's syndrome, left shoulder
M05.021	Felty's syndrome, right elbow
M05.022	Felty's syndrome, left elbow

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required and Typical Authorization Durations

Prior authorization is required. Initial and continuation authorizations are indication‑specific and have typical maximum durations (up to 12 months for chronic indications such as RA, GCA, SJIA, PJIA). Acute/short‑course indications (e.g., CRS, checkpoint inhibitor toxicities, acute GVHD) have shorter, indication‑specific authorization limits (see related callouts).

Initial authorizations for chronic rheumatologic and juvenile indications: up to 12 months.
Initial/continuation authorizations for CRS, acute GVHD, and checkpoint inhibitor‑related toxicities: limited to no more than 4 doses (or as specified).

Documentation Required

Prior Authorization — Link to Guidelines / Evidence

Authorization decisions require documentation that links the request to guideline or evidence‑based recommendations (e.g., ACR JIA/RA guidance, NCCN recommendations for CRS/GVHD/immune‑checkpoint toxicities). Include citations or notes to guideline sections when available.

Background and Rationale

Tocilizumab (intravenous) is a recombinant humanized monoclonal antibody that acts as an interleukin‑6 (IL‑6) receptor antagonist, binding both soluble and membrane‑bound IL‑6 receptors to inhibit IL‑6 signaling. Indications discussed in this policy include rheumatoid arthritis, polyarticular and systemic juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome (including CAR T‑cell‑related CRS), and steroid‑refractory acute graft‑versus‑host disease. The policy distinguishes IV administration (medical benefit) from subcutaneous self‑administration (pharmacy benefit).

Definitions and Key Terms

Tocilizumab (policy definition)

Policy scope (tocilizumab)Refers to intravenous infusion tocilizumab products only: Actemra, Avtozma, Tofidence, Tyenne, and any FDA‑approved biosimilars

ExclusionSubcutaneous self‑administered tocilizumab formulations are covered under the pharmacy benefit (not by this medical benefit policy)

Non‑preferred biosimilars noteAny FDA‑approved tocilizumab biosimilar not listed will be considered non‑preferred until reviewed by UnitedHealthcare

Steroid‑refractory acute GVHD

DefinitionAcute GVHD not adequately controlled by systemic corticosteroid therapy or when the patient is intolerant to systemic corticosteroid therapy

Policy operationalizationDiagnosis must be documented as 'steroid refractory' for initial tocilizumab consideration